Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Recruiting 2Active not recruiting 1

Sponsor Class

NIH 3

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 3

Conditions

Neoplasm Metastasis 36Leukemia, Myeloid, Acute 32Multiple Myeloma 27Lymphoma 23Breast Neoplasms 18Prostatic Neoplasms 17Pancreatic Neoplasms 17Colorectal Neoplasms 17Lymphoma, Large B-Cell, Diffuse 15Burkitt Lymphoma 15Myelodysplastic Syndromes 14Leukemia, Lymphocytic, Chronic, B-Cell 14Triple Negative Breast Neoplasms 12Ovarian Neoplasms 12Precursor Cell Lymphoblastic Leukemia-Lymphoma 11Melanoma 11Lung Neoplasms 11Sarcoma 10Lymphoma, T-Cell 9Glioma 9Carcinoma, Non-Small-Cell Lung 9Neuroblastoma 8Neoplasms 8Fallopian Tube Neoplasms 8Carcinoma, Renal Cell 8Squamous Cell Carcinoma of Head and Neck 7Lymphoma, Non-Hodgkin 7Lymphoma, Follicular 7Leukemia, Biphenotypic, Acute 7Endometrial Neoplasms 7

Interventions

Rituximab 5Specimen Handling 3Biopsy 3ibrutinib 2binimetinib 2Vemurafenib 2Cyclophosphamide 2Cladribine 2venetoclax 1tovorafenib 1polatuzumab vedotin 1pembrolizumab 1obinutuzumab 1immunotoxin HA22 1fludarabine phosphate 1fludarabine 1encorafenib 1acalabrutinib 1Whole-Body Irradiation 1Transplantation 1Tacrolimus 1Spinal Puncture 1Radiotherapy 1Prednisone 1Peripheral Blood Stem Cell Transplantation 1Mycophenolic Acid 1Magnetic Resonance Spectroscopy 1Lenalidomide 1High-Energy Shock Waves 1Famotidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Leukemia, Hairy Cell × Biopsy × 90 days × Clear all
NCT06965114 2026-06-03

Testing the Combination of Anti-cancer Drugs, Tovorafenib Plus Rituximab, in Patients With Hairy Cell Leukemia

National Cancer Institute (NCI)

Phase 1/2 Recruiting
84 enrolled
Other hematologic neoplasm

Leukemia, Hairy Cell

NCT01841723 2026-05-13

Ibrutinib in Treating Patients With Relapsed Hairy Cell Leukemia

National Cancer Institute (NCI)

Phase 2 Active not recruiting
44 enrolled
Other hematologic neoplasm

Leukemia, Hairy Cell

NCT06311227 2026-05-13

Venetoclax for the Treatment of Patients With Relapsed Hairy Cell Leukemia

National Cancer Institute (NCI)

Phase 2 Recruiting
20 enrolled
Other hematologic neoplasm

Leukemia, Hairy Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡